ARIBIOLAB 

AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment. It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster. Additionally, an influenza vaccine for seasonal flu, recombinant MBL for infectious disease suppression, and a TB booster vaccine. The company also develops 3rd-generation Hepatitis B vaccine (CVI HBV 001), a preventive vaccine using 3rd generation recombinant antigens; Hepatitis B therapeutic vaccine (CVI HBV 002), a therapeutic vaccine for treatment of patients and carriers of chronic hepatitis B; Shingles vaccine (CVI VZV 001), for prevention of shingles and postherpetic neuralgia; Next generation flu vaccine, quadrivalent influenza vaccine; Immunostimulant, TLR ligand based immunoreactive substances for immune response to vaccines; Recombinant MBL, immunotherapeutic substances infections by viruses and bacteria. The company was formerly known as CHA Vaccine Research Institute and changed its name to AriBioLab Co.,Ltd. in May 2026. AriBioLab Co.,Ltd. was incorporated in 2000 and is headquartered in Seongnam-si, South Korea.